Scholar Rock Holding (SRRK) Cash & Current Investments (2017 - 2026)
Scholar Rock Holding's quarterly Cash & Current Investments came in at $479.9 million in Q1 2026, up 31.72% year-on-year from $364.4 million in Q1 2025, and up 30.57% quarter-over-quarter from $367.6 million in Q4 2025.
Scholar Rock Holding has reported Cash & Current Investments for 10 years, with the latest figure at $479.9 million in Q1 2026.
- For the quarter ending Q1 2026, Cash & Current Investments rose 31.72% year-over-year to $479.9 million; the trailing twelve-month figure through Mar 2026 stood at $479.9 million (up 31.72% YoY), and the FY2025 full-year result was $367.6 million, down 15.94% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $479.9 million, up from $367.6 million in the prior quarter.
- The five-year high for Cash & Current Investments was $479.9 million in Q1 2026, with the low at $139.1 million in Q3 2024.
- Average Cash & Current Investments over 5 years is $302.6 million, with a median of $295.0 million recorded in 2025.
- Year-over-year, Cash & Current Investments sank 36.39% in 2024 and surged 165.8% in 2025.
- Tracing SRRK's Cash & Current Investments over 5 years: stood at $315.4 million in 2022, then slipped by 11.23% to $279.9 million in 2023, then soared by 56.21% to $437.3 million in 2024, then decreased by 15.94% to $367.6 million in 2025, then surged by 30.57% to $479.9 million in 2026.
- The last three Cash & Current Investments figures came in at $479.9 million (Q1 2026), $367.6 million (Q4 2025), and $369.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.13 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | 479.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 479.94 Mn |
| Dec 31, 2025 | 367.56 Mn |
| Sep 30, 2025 | 369.63 Mn |
| Jun 30, 2025 | 295.01 Mn |
| Mar 31, 2025 | 364.38 Mn |
| Dec 31, 2024 | 437.28 Mn |
| Sep 30, 2024 | 139.07 Mn |
| Jun 30, 2024 | 190.49 Mn |
| Mar 31, 2024 | 238.43 Mn |
| Dec 31, 2023 | 279.94 Mn |
| Sep 30, 2023 | 218.64 Mn |
| Jun 30, 2023 | 248.73 Mn |
| Mar 31, 2023 | 275.28 Mn |
| Dec 31, 2022 | 315.36 Mn |
| Sep 30, 2022 | 343.66 Mn |
| Jun 30, 2022 | 370.69 Mn |
| Mar 31, 2022 | 210.21 Mn |
| Dec 31, 2021 | 252.99 Mn |
| Sep 30, 2021 | 246.44 Mn |
| Jun 30, 2021 | 282.22 Mn |
| Mar 31, 2021 | 314.69 Mn |
| Dec 31, 2020 | 341.03 Mn |
| Sep 30, 2020 | 116.26 Mn |
| Jun 30, 2020 | 141.18 Mn |
| Mar 31, 2020 | 160.65 Mn |
| Dec 31, 2019 | 157.45 Mn |
| Sep 30, 2019 | 176.08 Mn |
| Jun 30, 2019 | 185.13 Mn |
| Mar 31, 2019 | 159.67 Mn |
| Dec 31, 2018 | 175.65 Mn |
| Sep 30, 2018 | 103.99 Mn |
| Jun 30, 2018 | 115.06 Mn |
| Dec 31, 2017 | 57.96 Mn |